Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 6, 2014, Pages 881-888

  Loukovaara, Sirpa ^a   Lehti, Kaisa ^b   Robciuc, Alexandra ^c,d   Pessi, Timo ^e   Holopainen, Juha M ^c   Koli, Katri ^b   Immonen, Ilkka ^a   Keski Oja, Jorma ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e Datawell Oy   (Finland)

Author keywords

Angiopoietin 1; Angiopoietin 2; Endothelial cell; Erythropoietin; Matrix metalloproteinases; Proliferative vitreoretinopathy; Rhegmatogenous retinal detachment; Transforming growth factor 1; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; GELATIN; GELATINASE A; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; ANGPT1 PROTEIN, HUMAN; ANGPT2 PROTEIN, HUMAN; BIOLOGICAL MARKER; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; MATRIX METALLOPROTEINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETINA DETACHMENT; RETINA MACULA HOLE; SEX RATIO; VITRECTOMY; VITREOUS BODY; ZYMOGRAPHY; AGED; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; RETINAL DETACHMENT;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DETACHMENT; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84902263299     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2508-z     Document Type: Article

References (54)

1. Lewis GP, Guerin CJ, Anderson DH, Matsumoto B, Fisher SK (1994) Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment. Am J Ophthalmol 118:368-376 (Pubitemid 24281731)
2. Cook B, Lewis GP, Fisher SK, Adler R (1995) Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 36:990-996
3. Mitry D, Fleck BW, Wright AF, Campbell H, Charteris DG (2010) Pathogenesis of rhegmatogenous retinal detachment - predisposing anatomy and cell biology. Retina 30:1561-1572
4. Lo ACY, Woo TTY, Wong RLM, Wong D (2011) Apoptosis and other cell deathmechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica 226(suppl 1):10-17
5. Hui YH, Goodnight R, Zhang XJ, Sorgente N, Ryan SJ (1988) Glial epiretinal membranes and contraction. Immunohistochemical and morphological studies. Arch Ophthalmol 106:1280-1285
6. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450 (Pubitemid 24307211)
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.N Engl JMed 331:1480-1487 (Pubitemid 24356306)
8. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol 133:851-852 (Pubitemid 34580647)
9. Kvanta A (2006) Ocular angiogenesis: the role of growth factors. Review article. Acta Ophthalmol Scand 84:282-288
10. Rasier R, Gormus U, Artunay O, Yuzbasioglu E, Oncel M, Bahcecioglu H (2010) Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye Res 35(6):505-509
11. Ricker LJAG, Diedonne SC, Kessels AG, Rennel ES, Berendschot TT, Hendrikse F, Kijlstra A, La Heij EC (2012) Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina 32(1):54-59
12. Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552-558 (Pubitemid 44780853)
13. Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, Peschos D, Psilas K, Agnantis NJ (2005) Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract 59(10):1157-1161 (Pubitemid 43904521)
14. Roberts A, Sporn MB (1993) Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8:1-9 (Pubitemid 23093206)
15. Sivak JM, Fini ME (2002) MMPs in the eye: emerging roles if or matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 21:1-14 (Pubitemid 34242704)
16. Brown D, Hamdi H, Bahri S, Kennedy MC (1994) Characterization of an endogenous metalloproteinase in human vitreous. Curr Eye Res 13:639-647 (Pubitemid 24275596)
17. Abu El-Asrar AM, Dralands L, Veckeneer M, Geboes K, Missotten L, Van Aelst I, Opdenakker G (1998) Gelatinase B in proliferative vitreoretinal disorders. Am J Ophthalmol 125:844-851 (Pubitemid 28283745)
18. De La Paz MA, Itoh Y, Toth CA, Nagase H (1998) Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci 39:1256-1260 (Pubitemid 28247362)
19. Kosano H, Okano T, Katsura Y, Noritake M, Kado S, Matsuoka T, Nishigori H (1999) ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64:2307-2315 (Pubitemid 29274224)
20. Das A, McGuire PG, Eriqat C, Ober RR, DeJuan E Jr, Williams GA, McLamore A, Biswas J, Johnson DW (1999) Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40:809-813 (Pubitemid 29109465)
21. Salzmann J, Limb GA, Khaw PT, Gregor ZJ, Webster L, Chignell AH, Charteris DG (2000) Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 84:1091-1096
22. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21:28-33 (Pubitemid 32151759)
23. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44(5):2163-2170 (Pubitemid 36520313)
24. Beránek M, Kolar P, Tschoplova S, Kankova K, Vasku A (2008) Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 14(14):1114-1121 (Pubitemid 351850566)
25. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT (1998) A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 39(8):1524-1529 (Pubitemid 28307381)
26. Symeonidis C, Diza E, Papakonstantinou E, Souliou E, Dimitrakos SA, Karakiulakis G (2007) Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. Retina 27(9):1279-1285 (Pubitemid 350211538)
27. Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E (2011) Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol Scand 89(4):339-345
28. Simo R, Carrasco E, Garcia-Remez M, Hernandez C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diab Rev 2:71-98 (Pubitemid 44082952)
29. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A (1999) Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol Diabetes 107:21-28 (Pubitemid 29082063)
30. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105(45):17504-17509
31. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S (2005) Erythropoietin as a retinal angiogenic factor. N Engl J Med 353:2190-2191
32. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782-792 (Pubitemid 41215487)
33. Caprara C, Grimm C (2012) From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res 31:89-119
34. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Ceramil A, Brines M, Rosenbaum DM (2002) Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. PNAS 16:10659-10664
35. Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M, Tanihara H (2004) Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 15:877-879 (Pubitemid 38453478)
36. Retina Society Terminology Committee (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112:159-165
37. Saharinen P, Alitalo K (2011) The yin, the yang, and the angiopoietin-1. J Clin Invest 121(6):2157-2159
38. Lohi J, Lehti K, Westermarck J, Kahari VM, Keski-Oja J (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239(2):239-247 (Pubitemid 26246526)
39. Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99:11205-11210 (Pubitemid 34920903)
40. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60 (Pubitemid 27450643)
41. Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA (2004) Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11(19):865-873 (Pubitemid 38714590)
42. Thurston G, Rudge J, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460-463 (Pubitemid 30208166)
43. Kim I, Moon S-O, Park SK (2001) Angiopoietin-1 reduces VEGF-stimulated leucocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin Expression. Circ Res 89:477-479 (Pubitemid 34132640)
44. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY (1999) Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448:249-253 (Pubitemid 29168496)
45. Brindle NPJ, Saharinen P, Alitalo K (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98:1014-1023
46. Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL, Rahn P, Christiaans SC, Bir ND, Pittet JF (2008) Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann Surg 247(2):320-326 (Pubitemid 351156777)
47. Sieczkiewicz GJ, Herman IM (2003) TGF-beta 1 signaling controls retinal pericyte cotractile protein expression. Microvasc Res 66:190-196 (Pubitemid 37373593)
48. Hoerster R, Hermann MM, Rosentreter A, Muether PS, Kirchhof B, Fauser S (2013) Profibrotic cytokines in aqueous humor correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol 97:450-453
49. Pfeffer BA, Flanders KC, Guerin CJ (1994) Transforming growth factor beta2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res 59:323-333 (Pubitemid 24326996)
50. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M (2009) The transforming growth factor-[beta] pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58(7):1659-1667
51. Xie Z, Wu X, Qiu Q, Gong Y, Song Y, Gu Q, Li C (2007) Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment. Curr Eye Res 32:757-764 (Pubitemid 47450627)
52. Wang ZY, Shen LJ, Zhao KK, Song ZM, Qu J (2009) Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Ophthalmic Res 42(3):138-140
53. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui T-G, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822-7835 (Pubitemid 39446915)
54. Shitama T, Hayashi H, Noge S (2008) Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2(9):1265-1280